Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Explore wealth management tips tailored to high income individuals, emphasizing diversified investments and efficient tax planning.
26,310 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Oklo shares jumped after the NRC cleared a foundational design criterion for the Aurora project, boosting the nuclear...
April brought a surprising surge for Tower Semiconductor, defying the notion that only the biggest chipmakers can mov...
Wix.com stock plummeting today is a reminder that even fast-growing tech names face headwinds. This guide breaks down...
An FDA leadership shakeup deepens as Tracy Hoeg publicly says she was fired, prompting questions about regulatory dir...
Rivian sits at a pivotal crossroads. This in-depth look weighs cash, partnerships, and a road map for growth to answe...
Two leaders, two paths: Nuscale Power’s SMRs and Nano Nuclear Energy’s microreactors. This guide breaks down commerci...
As Salesforce charts its path to 2027 earnings, investors weigh growth against profitability. This guide breaks down ...
The oil ETF that doubled in 2026 is navigating a renewed tug of war between supply shocks and capacity restoration. H...
As travel demand rebounds, investors want clarity on which cruise stock to buy in 2026. This guide contrasts Royal Ca...
A bold investing idea sits beyond Nvidia: a mid-sized AI semiconductor stock poised to outrun the market over the nex...
Bitcoin hovers near the $62,000 mark as geopolitical tensions flare and inflation prints ignite bets on rates. The cr...